Search

Your search keyword '"Mantegazza, Renato"' showing total 1,083 results
Start Over Author "Mantegazza, Renato"
1,083 results on '"Mantegazza, Renato"'

151. Rare variants in SQSTM1 and VCP genes and risk of sporadic inclusion body myositis

Author

Hanna, Michael G., Houlden, Henry, Machado, Pedro M., Gang, Qiang, Bettencourt, Conceicao, Healy, Estelle, Parton, Matthew, Holton, Janice L., Brady, Stefen, Hilton-Jones, David, Shieh, Perry B., Zanoteli, Edmar, de Camargo, Leonardo Valente, De Paepe, Boel, De Bleecker, Jan, Shaibani, Aziz, Ripolone, Michela, Violano, Raffaella, Moggio, Maurizio, Barohn, Richard J., Dimachkie, Mazen M., McVey, April L., Pasnoor, Mamatha, Glenn, Melanie, Jawdat, Omar, Statland, Jeffrey, Rico, Gabrielle, Mora, Marina, Mantegazza, Renato, Zanotti, Simona, Needham, Merrilee, Mastaglia, Frank, Liang, Christina, Dalakas, Marinos C., Biba, Angie, Chinoy, Hector, Lilleker, James B., Lamb, Janine, Platt, Hazel, Cooper, Robert G., Miller, James A.L., Roberts, Mark, Househam, Elizabeth, Hilton, David, Shivane, Aditya, Bartlett, Amy, Kissel, John T., Runk, Heidi, Wicklund, Matthew, Saperstein, David S., McKinney, Lynette R., Bettencourt, Conceição, Pittman, Alan M., Hughes, Deborah, and Singleton, Andrew B.

Published
2016
Full Text
View/download PDF

154. Patient-reported impact of myasthenia gravis in the real world: protocol for a digital observational study (MyRealWorld MG)

Author

Berrih-Aknin, Sonia, primary, Claeys, Kristl G, additional, Law, Nancy, additional, Mantegazza, Renato, additional, Murai, Hiroyuki, additional, Saccà, Francesco, additional, Dewilde, Sarah, additional, Janssen, Mathieu F, additional, Bagshaw, Emma, additional, Kousoulakou, Hara, additional, Larkin, Mark, additional, Beauchamp, Jon, additional, Leighton, Trevor, additional, and Paci, Sandra, additional

Published
2021
Full Text
View/download PDF

155. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial

Author

Howard, James F, primary, Bril, Vera, additional, Vu, Tuan, additional, Karam, Chafic, additional, Peric, Stojan, additional, Margania, Temur, additional, Murai, Hiroyuki, additional, Bilinska, Malgorzata, additional, Shakarishvili, Roman, additional, Smilowski, Marek, additional, Guglietta, Antonio, additional, Ulrichts, Peter, additional, Vangeneugden, Tony, additional, Utsugisawa, Kimiaki, additional, Verschuuren, Jan, additional, Mantegazza, Renato, additional, De Bleecker, Jan L., additional, De Koning, Kathy, additional, De Mey, Katrien, additional, De Pue, Annelien, additional, Mercelis, Rudolf, additional, Wyckmans, Maren, additional, Vinck, Caroline, additional, Wagemaekers, Linda, additional, Baets, Jonathan, additional, Ng, Eduardo, additional, Shabanpour, Jafar, additional, Daniyal, Lubna, additional, Mannan, Shabber, additional, Katzberg, Hans D., additional, Genge, Angela, additional, Siddiqi, Zaeem, additional, Junkerová, Jana, additional, Horakova, Jana, additional, Reguliova, Katerina, additional, Tyblova, Michaela, additional, Jurajdova, Ivana, additional, Novakova, Iveta, additional, Jakubikova, Michala, additional, Pitha, Jiri, additional, Vohanka, Stanislav, additional, Havelkova, Katerina, additional, Horak, Tomas, additional, Bednarik, Josef, additional, Horakova, Mageda, additional, Meisel, Andreas, additional, Remstedt, Dike, additional, Heibutzki, Claudia, additional, Kohler, Siegfried, additional, Gerischer, Lea, additional, Hoffman, Sarah, additional, Stascheit, Frauke, additional, Vissing, John, additional, Zafirakos, Lizzie, additional, Khatri, Kuldeep Kumar, additional, Autzen, Anne, additional, Godtfeldt Stemmerik, Mads Peter, additional, Andersen, Henning, additional, Attarian, Shahram, additional, Salort-Campana, Emmanuelle, additional, Delmont, Emilien, additional, Grapperon, Aude-Marie, additional, Kouton, Ludivine, additional, Tsiskaridze, Alexander, additional, Rózsa, Csilla, additional, Jakab, Gedeonne Margo, additional, Toth, Szilvia, additional, Szabo, Gyorgyi, additional, Bors, David, additional, Szabo, Eniko, additional, Campanella, Angela, additional, Vanoli, Fiammetta, additional, Frangiamore, Rita, additional, Antozzi, Carlo, additional, Bonanno, Silvia, additional, Maggi, Lorenzo, additional, Giossi, Riccardo, additional, Saccà, Francesco, additional, Marsili, Angela, additional, Pane, Chiara, additional, Puorro, Giorgia, additional, Reia, Antonio, additional, Antonini, Giovanni, additional, Alfieri, Girolamo, additional, Morino, Stefania, additional, Garibaldi, Matteo, additional, Fionda, Laura, additional, Leonardi, Luca, additional, Konno, Shingo, additional, Uzawa, Akiyuki, additional, Sakuma, Kaoru, additional, Watanabe, Chiho, additional, Ozawa, Yukiko, additional, Yasuda, Manato, additional, Onishi, Yosuke, additional, Samukawa, Makoto, additional, Tsuda, Tomoko, additional, Suzuki, Yasushi, additional, Ishida, Sayaka, additional, Watanabe, Genya, additional, Takahashi, Masanori, additional, Nakamura, Hiroko, additional, Sugano, Erina, additional, Kubota, Tomoya, additional, Imai, Tomihiro, additional, Suzuki., Mari, additional, Mori, Ayako, additional, Yamamoto, Daisuke, additional, Ikeda, Kazuna, additional, Hisahara, Shin, additional, Masuda, Masayuki, additional, Takaki, Miki, additional, Minemoto, Kanako, additional, Ido, Nobuhiro, additional, Naito, Makiko, additional, Okubo, Yoshihiko, additional, Sugimoto, Takamichi, additional, Takematsu, Yuka, additional, Kamei, Ayumi, additional, Shimizu, Mihiro, additional, Naito, Hiroyuki, additional, Nomura, Eiichi, additional, Van Heur, Marjolein, additional, Peters, Anne-Marie, additional, Tannemaat, Martijn, additional, Ruiter, Annabel, additional, Keene, Kevin, additional, Halas, Marek, additional, Szczudlik, Andrzej, additional, Pinkosz, Marta, additional, Frasinska, Monika, additional, Zwolinska, Grazyna, additional, Kostera-Pruszczyk, Anna, additional, Golenia, Aleksandra, additional, Szczudlik, Piotr, additional, Szczechowski, Lech, additional, Pasko, Aneta, additional, Poverennova, Irina, additional, Urtaeva, Lubov, additional, Kuznetsova, Nadezhda, additional, Romanova, Tatiana, additional, Nadezhda, Malkova, additional, Lapochka, Elena, additional, Korobko, Denis, additional, Vergunova, Ilona, additional, Melnikova, Anna, additional, Bulatova, Ekaterina, additional, Antipenko, Elena, additional, Basta, Ivana, additional, Bozovic, Ivo, additional, Lavrnic, Dragana, additional, Stojanovic, Vidosava Rakocevic, additional, Beydoun, Said, additional, Akhter, Salma, additional, Malekniazi, Ali, additional, Darki, Leila, additional, Pimentel, Norianne, additional, Cannon, Victoria, additional, Chopra, Manisha, additional, Traub, Rebecca, additional, Mozaffar, Tahseen, additional, Hernandez, Isela, additional, Turner, Ivonne, additional, Habib, Ali, additional, Goyal, Namita, additional, Kak, Manisha, additional, Velasquez, Erik, additional, Lam, Lucy, additional, Suresh, Niraja, additional, Farias, Jerrica, additional, Jones, Sarah, additional, Wagoner, Mary, additional, Eggleston, Debbie, additional, Bertorini, Tulio, additional, Benzel, Cindy, additional, Henegar, Robert, additional, Pillai, Rekha, additional, Bharavaju-Sanka, Ratna, additional, Paiz, Carolyn, additional, Jackson, Carlayne, additional, Ruzhansky, Katherine, additional, Dimitrova, Diana, additional, Visser, Amy, additional, Chahin, Nizar, additional, Levine, Todd, additional, Lisak, Robert, additional, Jia, Kelly, additional, Mada, Flicia, additional, Bernitsas, Evanthia, additional, Pasnoor, Mamatha, additional, Roath, Katherine, additional, Colgan, Samantha, additional, Currence, Melissa, additional, Heim, Andrew, additional, Barohn, Richard, additional, Dimachkie, Mazen, additional, Statland, Jeffrey, additional, Jawdat, Omar, additional, Jabari, Duaa, additional, Farmakidis, Constantine, additional, Gilchrist, James, additional, Li, Yuebing, additional, Caristo, Irys, additional, Hastings, Debbie, additional, Morren, John Anthony, additional, Weiss, Michael, additional, Muppidi, Srikanth, additional, Nguyen, Tia, additional, Welsh, Lesly, additional, So, Yuen, additional, Goyal, Neelam, additional, Pulley, Michael, additional, Bailey, Cathy, additional, Quraishi, Zubair, additional, Berger, Alan, additional, Sahagian, Gregory, additional, Camberos, Yasmin, additional, and Frishberg, Benjamin, additional

Published
2021
Full Text
View/download PDF

157. Next-Generation Sequencing Identifies Extended HLA Class I and II Haplotypes Associated With Early-Onset and Late-Onset Myasthenia Gravis in Italian, Norwegian, and Swedish Populations

Author

Creary, Lisa E., primary, Gangavarapu, Sridevi, additional, Caillier, Stacy J., additional, Cavalcante, Paola, additional, Frangiamore, Rita, additional, Lie, Benedicte A., additional, Bengtsson, Mats, additional, Harbo, Hanne Flinstad, additional, Brauner, Susanna, additional, Hollenbach, Jill A., additional, Oksenberg, Jorge R., additional, Bernasconi, Pia, additional, Maniaol, Angelina Hatlø, additional, Hammarström, Lennart, additional, Mantegazza, Renato, additional, and Fernández-Viña, Marcelo A., additional

Published
2021
Full Text
View/download PDF

158. Next-Generation Sequencing Identifies Extended HLA Class I and II Haplotypes Associated With Early-Onset and Late-Onset Myasthenia Gravis in Italian, Norwegian, and Swedish Populations

Author

Creary, Lisa E., Gangavarapu, Sridevi, Caillier, Stacy J., Cavalcante, Paola, Frangiamore, Rita, Lie, Benedicte A., Bengtsson, Mats, Harbo, Hanne Flinstad, Brauner, Susanna, Hollenbach, Jill A., Oksenberg, Jorge R., Bernasconi, Pia, Hatlø Maniaol, Angelina, Hammarström, Lennart, Mantegazza, Renato, Fernández-Viña, Marcelo A., Creary, Lisa E., Gangavarapu, Sridevi, Caillier, Stacy J., Cavalcante, Paola, Frangiamore, Rita, Lie, Benedicte A., Bengtsson, Mats, Harbo, Hanne Flinstad, Brauner, Susanna, Hollenbach, Jill A., Oksenberg, Jorge R., Bernasconi, Pia, Hatlø Maniaol, Angelina, Hammarström, Lennart, Mantegazza, Renato, and Fernández-Viña, Marcelo A.

Abstract

Genetic susceptibility to myasthenia gravis (MG) associates with specific HLA alleles and haplotypes at the class I and II regions in various populations. Previous studies have only examined alleles at a limited number of HLA loci that defined only broad serotypes or alleles defined at the protein sequence level. Consequently, genetic variants in noncoding and untranslated HLA gene segments have not been fully explored but could also be important determinants for MG. To gain further insight into the role of HLA in MG, we applied next-generation sequencing to analyze sequence variation at eleven HLA genes in early-onset (EO) and late-onset (LO) non-thymomatous MG patients positive for the acetylcholine receptor (AChR) antibodies and ethnically matched controls from Italy, Norway, and Sweden. For all three populations, alleles and haplotype blocks present on the ancestral haplotype AH8.1 were associated with risk in AChR-EOMG patients. HLA-B*08:01:01:01 was the dominant risk allele in Italians (OR = 3.28, P = 1.83E−05), Norwegians (OR = 3.52, P = 4.41E−16), and in Swedes HLA-B*08:01 was the primary risk allele (OR = 4.24, P <2.2E-16). Protective alleles and haplotype blocks were identified on the HLA-DRB7, and HLA-DRB13.1 class II haplotypes in Italians and Norwegians, whereas in Swedes HLA-DRB7 exhibited the main protective effect. For AChR-LOMG patients, the HLA-DRB15.1 haplotype and associated alleles were significantly associated with susceptibility in all groups. The HLA-DR13–HLA-DR–HLA-DQ haplotype was associated with protection in all AChR-LOMG groups. This study has confirmed and extended previous findings that the immunogenetic predisposition profiles for EOMG and LOMG are distinct. In addition, the results are consistent with a role for non-coding HLA genetic variants in the pathogenesis of MG.

Published
2021
Full Text
View/download PDF

159. Patient-reported impact of myasthenia gravis in the real world:Protocol for a digital observational study (MyRealWorld MG)

Author

Berrih-Aknin, Sonia, Claeys, Kristl G., Law, Nancy, Mantegazza, Renato, Murai, Hiroyuki, Saccà, Francesco, Dewilde, Sarah, Janssen, Mathieu F., Bagshaw, Emma, Kousoulakou, Hara, Larkin, Mark, Beauchamp, Jon, Leighton, Trevor, Paci, Sandra, Berrih-Aknin, Sonia, Claeys, Kristl G., Law, Nancy, Mantegazza, Renato, Murai, Hiroyuki, Saccà, Francesco, Dewilde, Sarah, Janssen, Mathieu F., Bagshaw, Emma, Kousoulakou, Hara, Larkin, Mark, Beauchamp, Jon, Leighton, Trevor, and Paci, Sandra

Abstract

Introduction Myasthenia gravis (MG) is a rare, chronic, autoimmune disease, mediated by immunoglobulin G antibodies, which causes debilitating muscle weakness. As with most rare diseases, there is little patient-reported data with which to understand and address patient needs. This study explores the impact of MG in the real world from the patient perspective. Methods and analysis This is a 2-year prospective, observational, digital, longitudinal study of adults with MG, resident in the following countries: the USA, Japan, Germany, France, the UK, Italy, Spain, Canada and Belgium. The planned sample size is 2000. Recruitment will be community based, via patient advocacy groups, social media and word of mouth. Participants will use a smartphone application (app) to check eligibility, provide consent and contribute data. Planned data entry is as follows: (1) personal profile on enrollment - covering demographics, MG characteristics and previous care; (2) monthly event tracker - current treatments, healthcare visits, treatment-related adverse events, productivity losses; (3) monthly selection of validated generic and disease-specific patient-reported outcomes instruments: EQ-5D-5L, Myasthenia Gravis Activities of Daily Living, Myasthenia Gravis Quality of Life 15-item revised scale, Hospital Anxiety and Depression Scale and Health Utilities Index III. Analyses are planned for when the study has been running in most countries for approximately 6, 12, 18 and 24 months. Ethics and dissemination The study protocol has been reviewed and granted ethics approval by Salus IRB for participants resident in the following countries: Germany, the UK and the US. Local ethics approval is being sought for the following study countries: Belgium, Canada, France, Italy, Japan and Spain. Study results will be communicated to the public and participants via conference presentations and journal publications, as well as regular email, social media and in-application communication. Trial r

Published
2021

160. Quantitative Muscle MRI Protocol as Possible Biomarker in Becker Muscular Dystrophy

Author

Beeldverwerking ISI, Brain, Maggi, Lorenzo, Moscatelli, Marco, Frangiamore, Rita, Mazzi, Federica, Verri, Mattia, De Luca, Alberto, Pasanisi, Maria Barbara, Baranello, Giovanni, Tramacere, Irene, Chiapparini, Luisa, Bruzzone, Maria Grazia, Mantegazza, Renato, Aquino, Domenico, Beeldverwerking ISI, Brain, Maggi, Lorenzo, Moscatelli, Marco, Frangiamore, Rita, Mazzi, Federica, Verri, Mattia, De Luca, Alberto, Pasanisi, Maria Barbara, Baranello, Giovanni, Tramacere, Irene, Chiapparini, Luisa, Bruzzone, Maria Grazia, Mantegazza, Renato, and Aquino, Domenico

Published
2021

161. Complement Inhibition for the Treatment of Myasthenia Gravis

Author

Mantegazza,Renato, Vanoli,Fiammetta, Frangiamore,Rita, and Cavalcante,Paola

Subjects
ImmunoTargets and Therapy
Abstract

Renato Mantegazza, Fiammetta Vanoli, Rita Frangiamore, Paola Cavalcante Neurology IV - Neuroimmunology and Neuromuscular Diseases Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, ItalyCorrespondence: Renato MantegazzaNeurology IV - Neuroimmunology and Neuromuscular Diseases Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Via Celoria 11, Milan 20133, ItalyTel +39-02-23942471Fax +39-02-23942413Email renato.mantegazza@istituto-besta.itAbstract: Generalized myasthenia gravis (gMG) is a rare autoimmune disorder affecting the neuromuscular junction (NMJ). Approximately 80– 90% of patients display antibodies directed against the nicotinic acetylcholine receptor (AChR). A major drive of AChR antibody-positive MG pathology is represented by complement activation. The role of the complement cascade has been largely demonstrated in patients and in MG animal models. Complement activation at the NMJ leads to focal lysis of the post-synaptic membrane, disruption of the characteristic folds, and reduction of AChR. Given that the complement system works as an activation cascade, there are many potential targets that can be considered for therapeutic intervention. Preclinical studies have confirmed the efficacy of complement inhibition in ameliorating MG symptoms. Eculizumab, an antibody directed towards C5, has recently been approved for the treatment of AChR antibody-positive gMG. Other complement inhibitors, targeting C5 as well, are currently under phase III study. Complement inhibitors, however, may present prohibitive costs. Therefore, the identification of a subset of patients more or less prone to respond to such therapies would be beneficial. For such purpose, there is a critical need to identify possible biomarkers predictive of therapeutic response, a field not yet sufficiently explored in MG. This review aims to give an overview of the complement cascade involvement in MG, the evolution of complement-inhibiting therapies and possible biomarkers useful to tailor and monitor complement-directed therapies.Keywords: myasthenia gravis, complement system, biological drugs, C5, biomarkers

Published
2020

173. Dysregulation of Muscle-Specific MicroRNAs as Common Pathogenic Feature Associated with Muscle Atrophy in ALS, SMA and SBMA: Evidence from Animal Models and Human Patients

Author

Malacarne, Claudia, primary, Galbiati, Mariarita, additional, Giagnorio, Eleonora, additional, Cavalcante, Paola, additional, Salerno, Franco, additional, Andreetta, Francesca, additional, Cagnoli, Cinza, additional, Taiana, Michela, additional, Nizzardo, Monica, additional, Corti, Stefania, additional, Pensato, Viviana, additional, Venerando, Anna, additional, Gellera, Cinzia, additional, Fenu, Silvia, additional, Pareyson, Davide, additional, Masson, Riccardo, additional, Maggi, Lorenzo, additional, Dalla Bella, Eleonora, additional, Lauria, Giuseppe, additional, Mantegazza, Renato, additional, Bernasconi, Pia, additional, Poletti, Angelo, additional, Bonanno, Silvia, additional, and Marcuzzo, Stefania, additional

Published
2021
Full Text
View/download PDF

174. Efgartigimod: A First-in-class Investigational Antibody Fragment for the Treatment of Generalized Myasthenia Gravis.

Author

Vanoli, Fiammetta and Mantegazza, Renato

Subjects
*MYASTHENIA gravis, *AUTOIMMUNITY, *THERAPEUTICS, *IMMUNOTHERAPY, *CHOLINERGIC receptors
Abstract

Myasthenia gravis (MG) is a rare autoimmune disorder characterized by fatigue and muscle weakness. About 85-90% of patients with generalized MG display pathogenic immunoglobulin (Ig)G antibodies against the skeletal muscle nicotinic acetylcholine receptor (AChR), the muscle-specific tyrosine kinase or the lipoprotein receptor-related protein, which all exert their effect by disrupting neuromuscular transmission. Therapy for MG includes immunomodulation and non-specific immunosuppression; the latter comprises corticosteroids and non-steroidal immunosuppressive therapies, which non-selectively suppress the immune system and are frequently accompanied by burdensome side effects. This, together with the fact that up to 20% of patients are refractory to immunosuppressive therapy, highlights a compelling unmet need for more effective and better-tolerated therapies. Efgartigimod, a humanized IgG1-derived fragment crystallizable region that competitively blocks the neonatal fragment crystallizable receptor, holds great promise in meeting this need, having good tolerability and a more targeted effect. Efgartigimod has been recently approved by the US Food and Drug Administration (FDA) for the treatment of AChR-positive patients with generalized MG, making it the first FDA-approved neonatal fragment crystallizable receptor antagonist. This review focuses on the clinical development of efgartigimod, which offers an encouraging new therapeutic option for generalized MG. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

175. Efficacy, Safety, and Tolerability of Efgartigimod in Patients With Generalized Myasthenia Gravis: Analysis of the Phase 3 ADAPT Study (4520)

Author

Howard, James, primary, Bril, Vera, additional, Vu, Tuan, additional, Karam, Chafic, additional, Peric, Stojan, additional, Murai, Hiroyuki, additional, Guglietta, Antonio, additional, Ulrichts, Peter, additional, Vangeneugden, Tony, additional, Utsugisawa, Kimiaki, additional, Verschuuren, Jan, additional, and Mantegazza, Renato, additional

Published
2021
Full Text
View/download PDF

177. Complement Inhibition for the Treatment of Myasthenia Gravis

Author

Mantegazza, Renato, Vanoli, Fiammetta, Frangiamore, Rita, and Cavalcante, Paola

Subjects
myasthenia gravis, biomarkers, Review, myasthenia gravis, complement system, biological drugs, C5, biomarkers, complement system, C5, biological drugs
Abstract

Generalized myasthenia gravis (gMG) is a rare autoimmune disorder affecting the neuromuscular junction (NMJ). Approximately 80–90% of patients display antibodies directed against the nicotinic acetylcholine receptor (AChR). A major drive of AChR antibody-positive MG pathology is represented by complement activation. The role of the complement cascade has been largely demonstrated in patients and in MG animal models. Complement activation at the NMJ leads to focal lysis of the post-synaptic membrane, disruption of the characteristic folds, and reduction of AChR. Given that the complement system works as an activation cascade, there are many potential targets that can be considered for therapeutic intervention. Preclinical studies have confirmed the efficacy of complement inhibition in ameliorating MG symptoms. Eculizumab, an antibody directed towards C5, has recently been approved for the treatment of AChR antibody-positive gMG. Other complement inhibitors, targeting C5 as well, are currently under phase III study. Complement inhibitors, however, may present prohibitive costs. Therefore, the identification of a subset of patients more or less prone to respond to such therapies would be beneficial. For such purpose, there is a critical need to identify possible biomarkers predictive of therapeutic response, a field not yet sufficiently explored in MG. This review aims to give an overview of the complement cascade involvement in MG, the evolution of complement-inhibiting therapies and possible biomarkers useful to tailor and monitor complement-directed therapies.

Published
2020

189. Nusinersen safety and effects on motor function in adult spinal muscular atrophy type 2 and 3

Author

Maggi, Lorenzo, primary, Bello, Luca, additional, Bonanno, Silvia, additional, Govoni, Alessandra, additional, Caponnetto, Claudia, additional, Passamano, Luigia, additional, Grandis, Marina, additional, Trojsi, Francesca, additional, Cerri, Federica, additional, Ferraro, Manfredi, additional, Bozzoni, Virginia, additional, Caumo, Luca, additional, Piras, Rachele, additional, Tanel, Raffaella, additional, Saccani, Elena, additional, Meneri, Megi, additional, Vacchiano, Veria, additional, Ricci, Giulia, additional, Soraru', Gianni, additional, D'Errico, Eustachio, additional, Tramacere, Irene, additional, Bortolani, Sara, additional, Pavesi, Giovanni, additional, Zanin, Riccardo, additional, Silvestrini, Mauro, additional, Politano, Luisa, additional, Schenone, Angelo, additional, Previtali, Stefano Carlo, additional, Berardinelli, Angela, additional, Turri, Mara, additional, Verriello, Lorenzo, additional, Coccia, Michela, additional, Mantegazza, Renato, additional, Liguori, Rocco, additional, Filosto, Massimiliano, additional, Marrosu, Gianni, additional, Siciliano, Gabriele, additional, Simone, Isabella Laura, additional, Mongini, Tiziana, additional, Comi, Giacomo, additional, and Pegoraro, Elena, additional

Published
2020
Full Text
View/download PDF

193. Clinical and Molecular Spectrum of Myotonia and Periodic Paralyses Associated With Mutations in SCN4A in a Large Cohort of Italian Patients

Author

Maggi, Lorenzo, primary, Brugnoni, Raffaella, additional, Canioni, Eleonora, additional, Tonin, Paola, additional, Saletti, Veronica, additional, Sola, Patrizia, additional, Piccinelli, Stefano Cotti, additional, Colleoni, Lara, additional, Ferrigno, Paola, additional, Pini, Antonella, additional, Masson, Riccardo, additional, Manganelli, Fiore, additional, Lietti, Daniele, additional, Vercelli, Liliana, additional, Ricci, Giulia, additional, Bruno, Claudio, additional, Tasca, Giorgio, additional, Pizzuti, Antonio, additional, Padovani, Alessandro, additional, Fusco, Carlo, additional, Pegoraro, Elena, additional, Ruggiero, Lucia, additional, Ravaglia, Sabrina, additional, Siciliano, Gabriele, additional, Morandi, Lucia, additional, Dubbioso, Raffaele, additional, Mongini, Tiziana, additional, Filosto, Massimiliano, additional, Tramacere, Irene, additional, Mantegazza, Renato, additional, and Bernasconi, Pia, additional

Published
2020
Full Text
View/download PDF

195. Cytokine Profile in Striated Muscle Laminopathies: New Promising Biomarkers for Disease Prediction

Author

Cappelletti, Cristina, primary, Tramacere, Irene, additional, Cavalcante, Paola, additional, Schena, Elisa, additional, Politano, Luisa, additional, Carboni, Nicola, additional, Gambineri, Alessandra, additional, D’Amico, Adele, additional, Ruggiero, Lucia, additional, Ricci, Giulia, additional, Siciliano, Gabriele, additional, Boriani, Giuseppe, additional, Mongini, Tiziana Enrica, additional, Vercelli, Liliana, additional, Biagini, Elena, additional, Ziacchi, Matteo, additional, D’Apice, Maria Rosaria, additional, Lattanzi, Giovanna, additional, Mantegazza, Renato, additional, Maggi, Lorenzo, additional, and Bernasconi, Pia, additional

Published
2020
Full Text
View/download PDF

196. Infection Risk in Patients with Complement-Mediated Neurological Disorders Receiving Eculizumab: Findings from Two Phase 3 Studies and Their Extensions in Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder (AQP4+ NMOSD) and Acetylcholine-Receptor Antibody-Positive Refractory Generalized Myasthenia Gravis (AChR+ gMG) (1829)

Author

Levine, Todd, primary, Mantegazza, Renato, additional, Oreja-Guevara, Celia, additional, Carrillo-Infante, Cynthia, additional, Kaprielian, Roger, additional, Shang, Shulian, additional, Yountz, Marcus, additional, and Howard, James, additional

Published
2020
Full Text
View/download PDF

197. Additional Analyses of the Phase 2 Efgartigimod Study in Myasthenia Gravis (4484)

Author

Howard, James, primary, Bril, Vera, additional, Mantegazza, Renato, additional, Beydoun, Said, additional, De Rivera Garrido, Fancisco Javier, additional, Piehl, Fredrik, additional, Rottoli, Maria Rosa, additional, Van Damme, Philip, additional, Vu, Tuan, additional, Ulrichts, Peter, additional, Guglietta, Antonio, additional, Beauchamp, Jon, additional, de Haard, Hans, additional, and Verschuuren, Jan, additional

Published
2020
Full Text
View/download PDF

199. Circulating MyomiRs as Potential Biomarkers to Monitor Response to Nusinersen in Pediatric SMA Patients

Author

Bonanno, Silvia, primary, Marcuzzo, Stefania, additional, Malacarne, Claudia, additional, Giagnorio, Eleonora, additional, Masson, Riccardo, additional, Zanin, Riccardo, additional, Arnoldi, Maria Teresa, additional, Andreetta, Francesca, additional, Simoncini, Ornella, additional, Venerando, Anna, additional, Gellera, Cinzia, additional, Pantaleoni, Chiara, additional, Mantegazza, Renato, additional, Bernasconi, Pia, additional, Baranello, Giovanni, additional, and Maggi, Lorenzo, additional

Published
2020
Full Text
View/download PDF

200. Quantitative Muscle MRI Protocol as Possible Biomarker in Becker Muscular Dystrophy

Author

Maggi, Lorenzo, primary, Moscatelli, Marco, additional, Frangiamore, Rita, additional, Mazzi, Federica, additional, Verri, Mattia, additional, De Luca, Alberto, additional, Pasanisi, Maria Barbara, additional, Baranello, Giovanni, additional, Tramacere, Irene, additional, Chiapparini, Luisa, additional, Bruzzone, Maria Grazia, additional, Mantegazza, Renato, additional, and Aquino, Domenico, additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results